Limitations of oral busulfan in preparative regimen before hematopoietic stem-cell transplantation.
Kami
Masahiro
M
Department of Medical Oncology, Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan.
Hamaki
Tamae
T
Maruta
Yumiko
Y
Miyakoshi
Shigesaburo
S
Mutou
Yoshitomo
Y
D000284:Administration, Oral; D000328:Adult; D000477:Alkylating Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D000927:Anticonvulsants / Q000627:therapeutic use; D002066:Busulfan / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D006261:Headache / Q000139:chemically induced; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced*; D010292:Paresthesia / Q000139:chemically induced; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014839:Vomiting / Q000139:chemically induced*
D000477:Alkylating Agents; D000927:Anticonvulsants; D002066:Busulfan